D. Positive Risk Factors 1
E. Negative Risk Factors 1. High HDL cholesterol: > or = 60 mg/dL, if so subtract one risk factor F. Drug Therapy Initiation Level LDL Goal Without CHD and with <2 risk factors > or = 190 mg/dL <160 mg/dL Without CHD and with > or=2 risk factors > or = 160 mg/dL <130 mg/dL With CHD >or= 130mg/dL <100 mg/dL G. Each 10% reduction in cholesterol levels is associated with a reduction of approximately 20% to 30% in the incidence of coronary heart disease. H. Because most cholesterol is carried by the HDL and LDL, it is important to target these especially in drug therapy. IV. Antihyperlipidemics List the potential drug classes that may be beneficial in the management of hyperlipidemia. A. Hydroxymethylglutaryl-Coenzyme reductase inhibitors (HMG-CoA) B. Bile Acid Sequestrants C. Cholesterol Absorption Inhibitors D. Fibric Acid Derivatives E. B Vitamin V. First-line drug therapy for hypercholesterolemia (elevated LDL cholesterol), the most dangerous form of dyslipidemia is Statins durg class. A. Five statins on the market 1. atorvastatin (Lipitor) – most commonly used 2. fluvastatin (Lescol) 3. lovastatin (Mevacor) –first used 4. pravstatin (Pravachol) 5. simvastatin (Zocor) B. Most common adverse effect: HA;GI: N/V: diarrhea; gallstones;GU: decreased urine output;hematuria; impotence and other: Drowsiness; dizziness; rash; priuritis; vertigo. C. Most serious adverse effect: Myopathy (muscle pain) and Rhabdomyolysis. D. Monitor liver and Kidney function tests prior to starting therapy, at 6 and 12 weeks after starting therapy or after each dose adjustment, and then every 6 months thereafter.
- Winter '16
- ldl cholesterol, ldl cholesterol levels